Advertisement

Prevention of Venous Thromboembolic Events With Low-Molecular-Weight Heparin in the Non-Major Orthopaedic Setting: Meta-Analysis of Randomized Controlled Trials

      Purpose

      To assess the efficacy of low-molecular-weight heparin (LMWH) venous thromboprophylaxis in patients with transient reduced mobility in the non-major orthopaedic setting.

      Methods

      A meta-analysis was conducted using data from all available randomized trials comparing LMWH with placebo or no prophylactic treatment in patients with leg immobilization for fracture or soft-tissue injury of the lower limb or in patients undergoing knee arthroscopy. The primary endpoint was the incidence of major venous thromboembolic events (VTEs), including asymptomatic proximal deep-vein thrombosis, symptomatic VTEs, and VTE-related death. The Mantel-Haenszel method was used to generate the summary statistics for the overall effect of LMWH.

      Results

      Fourteen studies were included (4,726 patients). The weighted rate of major VTEs was estimated to be 2.9% (95% confidence interval [CI], 2.2% to 3.7%) without LMWH prophylaxis. Overall, a significant 68% reduction in the risk of major VTEs was observed with LMWH prophylaxis (relative risk [RR], 0.32; 95% CI, 0.20 to 0.51; P < .001). The treatment effect was not modified by the clinical setting, that is, distal lower limb injury (7 studies; 1,711 patients; RR, 0.42; 95% CI, 0.20 to 0.86) or knee arthroscopy (6 studies; 2,428 patients; RR, 0.27; 95% CI, 0.15 to 0.49). A nonsignificant 35% increase in the risk of major bleeding was observed in the LMWH prophylaxis group (RR, 1.35; 95% CI, 0.53 to 3.47).

      Conclusions

      This meta-analysis indicates potential efficacy of LMWH in preventing thromboembolic events in patients with reduced mobility in the non-major orthopaedic setting compared with placebo or no treatment. However, the decision of whether to implement LMWH prophylaxis in each specific setting should also take into account the risk of VTEs in the absence of prophylaxis, the potential adverse effects of LMWH, and the cost.

      Level of Evidence

      Level II, meta-analysis of Level II studies or Level I studies with inconsistent results.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Arthroscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Société Française d'Anesthésie et de Réanimation. Prévention de la maladie thromboembolique veineuse périopératoire et obstétricale. Available from: http://www.sfar.org/_docs/articles/preventionmte_rpc.pdf. Accessed April 18, 2014.

        • Geerts W.H.
        • Bergqvist D.
        • Pineo G.F.
        • et al.
        Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
        Chest. 2008; 133: S381-S453
      2. National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: The management of venous thromboembolic diseases and the role of thrombophilia testing. Available from: URL: http://www.nice.org.uk/nicemedia/live/13767/59720/59720.pdf. Published June 2012. Accessed February 14, 2013.

        • Samama C.M.
        • Gafsou B.
        • Jeandel T.
        • et al.
        French Society of Anaesthesia and Intensive Care. Guidelines on perioperative venous thromboembolism prophylaxis. Update 2011. Short text.
        Ann Fr Anesth Reanim. 2011; 30 (in French): 947-951
        • Higgins J.P.
        • Altman D.G.
        • Gøtzsche P.C.
        • et al.
        The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
        BMJ. 2011; 343: d5928
      3. European Medicines Agency. Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products for prophylaxis of intra- and post-operative venous thromboembolic risk. Available from: URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003301.pdf. Published 2009. Accessed February 14, 2013.

        • Egger M.
        • Smith G.D.
        • Phillips A.N.
        Meta-analysis: Principles and procedures.
        BMJ. 1997; 315: 1533-1537
        • Sterne J.A.
        • Gavaghan D.
        • Egger M.
        Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature.
        J Clin Epidemiol. 2000; 53: 1119-1129
        • Kujath P.
        • Spannagel U.
        • Habscheid W.
        Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb.
        Haemostasis. 1993; 23: 20-26
        • Roth V.P.
        Thromboembolieprophylaxe bei ambulant durchgeführten arthroskopischen Meniskusoperationen.
        Orthop Prax. 1995; 5: 345-348
      4. Canata GL, Chiey A. Prevention of venous thromboembolism after ACL reconstruction: A prospective, randomized study. Presented at the International Society of Arthroscopy, Knee Surgery and Orthopedic Sports Medicine Congress; Auckland, New Zealand; March 10-13, 2003.

      5. Selby R, Geerts WH, Kreder HJ, et al. Clinically-important venous thromboembolism (CIVTE) following isolated leg fractures distal to the knee: Epidemiology and prevention: The D-KAF (Dalteparin in Knee to Ankle Fracture) trial. Presented at the XXI International Society on Thrombosis and Haemostasis Congress; Geneva, Switzerland; July 6-12, 2007.

        • Kock H.J.
        • Schmit-Neuerburg K.P.
        • Hanke J.
        • Rudofsky G.
        • Hirche H.
        Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg.
        Lancet. 1995; 346: 459-461
        • Jørgensen P.S.
        • Warming T.
        • Hansen K.
        • et al.
        Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: A venografic controlled study.
        Thromb Res. 2002; 105: 477-480
        • Lassen M.R.
        • Borris L.C.
        • Nakov R.L.
        Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization.
        N Engl J Med. 2002; 347: 726-730
        • Lapidus L.J.
        • Rosfors S.
        • Ponzer S.
        • et al.
        Prolonged thromboprophylaxis with dalteparin after surgical treatment of Achilles tendon rupture: A randomized, placebo-controlled study.
        J Orthop Trauma. 2007; 21: 52-57
        • Lapidus L.J.
        • Ponzer S.
        • Elvin A.
        • et al.
        Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: A randomized placebo-controlled, double-blind study.
        Acta Orthop. 2007; 78: 528-535
        • Goel D.P.
        • Buckley R.
        • deVries G.
        • Abelseth G.
        • Ni A.
        • Gray R.
        Prophylaxis of deep-vein thrombosis in fractures below the knee: A prospective randomised controlled trial.
        J Bone Joint Surg Br. 2009; 91: 388-394
        • Wirth T.
        • Schneider B.
        • Misselwitz F.
        • et al.
        Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial.
        Arthroscopy. 2001; 17: 393-399
        • Michot M.
        • Conen D.
        • Holtz D.
        • et al.
        Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low-molecular weight heparin.
        Arthroscopy. 2002; 18: 257-263
        • Marlovits S.
        • Striessnig G.
        • Schuster R.
        • et al.
        Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: A prospective, randomized, placebo-controlled study.
        Arthroscopy. 2007; 23: 696-702
        • Camporese G.
        • Bernardi E.
        • Prandoni P.
        • et al.
        Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: A randomized trial.
        Ann Intern Med. 2008; 149: 73-82
        • Ramos J.
        • Perrotta C.
        • Badariotti G.
        • Berenstein G.
        Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
        Cochrane Database Syst Rev. 2008; : CD005259
        • Testroote M.
        • Stigter W.A.H.
        • de Visser D.C.
        • Janzing H.M.J.
        Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization.
        Cochrane Database Syst Rev. 2008; : CD006681
        • Ettema H.B.
        • Kollen B.J.
        • Verheyen C.C.P.M.
        • Büller H.R.
        Prevention of venous thromboembolism in patients with immobilization of the lower extremities: A meta-analysis of randomized controlled trials.
        J Thromb Haemost. 2008; 6: 1093-1098
        • Gehling H.
        • Giannadakis K.
        • Lefering R.
        • Hessmann M.
        • Achenbach S.
        • Gotzen L.
        Prospective randomized pilot study of ambulatory prevention of thromboembolism. 2 times 500 mg aspirin (ASS) vs. clivarin 1750 (NMH).
        Unfallchirurg. 1998; 101 (in German): 42-49
        • Samama C.M.
        • Lecoules N.
        • Kierzek G.
        • et al.
        Comparison of fondaparinux in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury.
        J Thromb Haemost. 2013; 11: 1833-1843